MSF is concerned that certain clauses related to intellectual property in this trade deal could significantly undermine the use of existing public health measures enshrined in Indian patent law.
Indonesia's Ministry of Law and Human Rights discussed the intellectual property (IP) chapter during the 17th Round of Negotiations of the IEU-CEPA Working Group on Intellectual Property (WGIP).
Intellectual property protection for the Swiss pharmaceutical industry has been a key sticking point in negotiations on a free trade agreement with India. Now there seems to be a breakthrough in talks after 16 years. What’s changed?
The African Union is finalizing the draft protocol on intellectual property rights to the agreement establishing the African Continental Free Trade Area (AfCFTA).
The clause in the draft free trade agreement text could delay access to affordable, generic versions of patented drugs in India by a minimum of six years, according to documents.
The “TRIPS-Plus” provisions in the India-UK Agreement are a dangerous attempt to increase the power of pharmaceutical companies by placing profits before public health.
MSF and over 50 UK-based civil society organisations and individuals sent this open letter to United Kingdom Prime Minister, urging him to commit that the UK-India Free Trade Agreement will not gut the public health safeguards that are in India’s intellectual property laws.
The GCC deepens economic ties with major Asian partners, signing its second FTA this year, highlighting commitment to investment and economic diversification.